Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Russell

Showing results (1071-1080 of 1,120) with videos related to

Pageof 112
Sort By:
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood|February 27, 2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetMiguel A Sanz, Pierre Fenaux, Martin S Tallman, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Kidney360|April 4, 2022
Long-Term Impact of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients: A 5-Year Follow-Up Observational Cohort StudyTania Salehi, Nicholas J Montarello, Nishant Juneja, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood|August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AMLJad Othman, Nicola Potter, Sylvie D Freeman, et al.
British Journal of Haematology|May 22, 2001
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centresG Gahrton, H Svensson, M Cavo, et al.
Blood|August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trialSylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Pageof 112

Showing results (1071-1080 of 1,120) with videos related to

Sort By:
Pageof 112
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood|February 27, 2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetMiguel A Sanz, Pierre Fenaux, Martin S Tallman, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Kidney360|April 4, 2022
Long-Term Impact of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients: A 5-Year Follow-Up Observational Cohort StudyTania Salehi, Nicholas J Montarello, Nishant Juneja, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood|August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AMLJad Othman, Nicola Potter, Sylvie D Freeman, et al.
British Journal of Haematology|May 22, 2001
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centresG Gahrton, H Svensson, M Cavo, et al.
Blood|August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trialSylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Pageof 112